中文摘要：

目的：采用Meta分析评估舒血宁治疗慢性肺源性心脏病（ CPHD）的疗效性和安全性。方法舒血宁联合应用常规治疗（试验组）和常规治疗（对照组）均使用随机对照试验。检索Cochrane图书馆、Pubmed、中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊数据库和万方数据库检索相关文献。利用Cochrane评价法评价文献质量,进行资料提取并采用Rev-man 5．2软件对舒血宁的总体疗效进行数据分析。结果检测到符合要求的文献研究14篇。 Meta分析显示试验组的总疗效优于对照组,差异有统计学意义{RR=1．33,95% CI（1．25,1．41）,Z=8．94,P〈0．00001}；且不良反应轻微。结论舒血宁联合应用常规方案在治疗CPHD有显著的疗效。由于受到文献质量限制,建议该系统评价的结论在临床应用中应谨慎,并需要进行大规模的RCTs试验提供更佳的循证证据。

英文摘要：

Objective Provide a PRISMA-compliant meta analysis/systematic review to evaluate the efficacy and safe of SXL in treating CPHD. Methods RCTs involving SXL combined with conventional drugs（ experiment group） versus conventional drugs（ control group） were identified. Pubmed,Cochrane-library,Chinese Biomedical Literature Database,Chinese National Knowl-edge Infrastructure,Chinese Scientific Journal Database and Wanfang Med Online Database were used to searched criteria. Meta a-nalysis was used to evaluate the total effect of SXL. Rev Man 5. 2 was used for data analysis. Results 14 RCTs were included in this systematically reviewed. Statistical analysis of outcomes showed that experiment groups had significant difference due to impro-ving the total effect versus control groups{RR=1. 33,95% CI（1. 25,1. 41）,Z=8. 94,P〈0. 00001}. Conclusion SXL com-bined with conventional drugs appears to have some positive effects in treatment of CPHD with slight adverse reaction. Confined in the low quality of studies included,we suggest that our conclusions should be limited in the clinical working. Further rigorous de-signed RCTs are still needed.